Angiogenic tumor markers, antiangiogenic agents and radiation therapy

References

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl I Med. 285,1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• •The birth of modem angiogenesis.
   Google Scholar
• Fang J, Shing Y, Wiederschain D et al. Matrix met alloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl Acad. Sc]. USA 97(5), 3884–3889 (2000).
   Google Scholar
• Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. Bcr/abl induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-la, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (10), 3767–3775 (2002).
   Google Scholar
• Dvorak HF, Nagy JA, Berse B et al Vascular permeability factor, fibrin and the pathogenesis of the tumor stroma formation. Ann. NY Acad. Sc]. 667, 110–111 (1992).
   Google Scholar
• Rak J, Mitsuhashi Y, Bayko L et al Mutant ms oncogenes upregulate VEGF/VPK expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55,4574–4580 (1995).
   Google Scholar
• Kieser A, Weich HA, Brandner G, Marme D, Kolch W Mutant p53 potentiates protein kinase c induction of vascular endothelial growth factor expression. Oncogene 9,963–969 (1994).
   PubMed Web of Science ®Google Scholar
• McMahon G. VEGF receptor signaling in tumor angiogenesis. O1cologist5\(Suppl. 1), 3–10 (2000).
   Google Scholar
• Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin. North Am. 16(5), 1125 (2002).
   Google Scholar
• Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. j Clin. Oncol 19(4), 1207–1225 (2001).
   Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT et al Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59,3374–3378 (1999).
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Sako T, Shibao K et al Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res. 22(4), 2437–2442 (2002).
   Google Scholar
• Hormbrey E, Gillespie P, Turner K et al. A critical review of vascular endothelial growth factor analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis 19,651–663 (2002).
   PubMed Web of Science ®Google Scholar
• •Current controversy regarding analysis of vascular endothelial growth factor (VEGF) in peripheral blood.
   Google Scholar
• Vihinen P, Kahari VM. Matrix met alloproteinases in cancer: prognostic markers and therapeutic targets. int. J. Cancer99, 157–166 (2002).
   PubMed Web of Science ®Google Scholar
• Burke PA, DeNardo SJ. Anti-angiogenic agents and their promising potential in combined therapy. Grit. Rev Oncol Hematol 39,155–171 (2001).
   Google Scholar
• Itoh T, Tanioka M, Matsuda H et al Experimental metastasis is suppressed in MMP-9 deficient mice. Clin. Exp. Metastasis 17,177–181 (1999).
   Google Scholar
• Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase a-deficient mice. Cancer Res. 58, 1048–1051 (1998).
   PubMed Web of Science ®Google Scholar
• Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix met alloproteinases in urine of cancer patients. Cancer Res. 58(7), 1395–1399 (1998).
   Google Scholar
• Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol 16,3121–3128 (1998).
   PubMed Web of Science ®Google Scholar
• Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol 18, 2046–2052 (2000).
   Google Scholar
• Kraft A, Weindel K, Ochs A et al VEGF in the sera and effusions of patients with malignant and nonmalignant disease. Cancer85, 178–187 (1999).
   PubMed Web of Science ®Google Scholar
• Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5 (Suppl. 1), 45–50 (2000).
   Google Scholar
• Ondruschka C, Buhtz P, Motsch C et al Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res. Pract. 198(8), 509–515 (2002).
   Google Scholar
• Cai W Song JD. Expression of matrix met alloproteinase and tissue inhibitors in ovarian tumors. Ai Zheng21, 91–94 (2002).
   Google Scholar
• Lengyel E, Schmalfeldt B, Konik E et al Expression of latent matrix met alloproteinase-9 predicts survival inadvanced ovarian cancer. Cynecol Oncol 82(2), 291–298 (2001).
   Google Scholar
• Kuniyasu H, Ellis LM, Evans DB et al Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res 5,25–33 (1999).
   Google Scholar
• Sienel W, Hellers J, Morresi-Hauf A et al Prognostic impact of matrix met alloproteinase-9 in operable non-small cell lung cancer. Int. I Cancer 103(5), 647–651 (2003).
   Google Scholar
• Kuittinen 0, Soini Y, Turpeenniemi- Hujanen T Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur. I 1-Lematol 69(4), 205–212 (2002).
   Google Scholar
• Gerhards S, Jung K, Koenig F et al Excretion of matrix met alloproteinases-2 and -9 in urine is associated with a high stage and grade of bladder carcinoma. Urology57(4), 675–679 (2001).
   Google Scholar
• Kausch I, Bohle A. Molecular aspects of bladder cancer III: prognostic markers of bladder cancer. Eur Ural 41,15–29 (2002).
   PubMed Web of Science ®Google Scholar
• Gokaslan ZL, Chintala SK, York JE et al Expression and role of matrix met alloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis 16,721–728 (1998).
   Google Scholar
• Kanoh Y, Akahoshi T, Ohara T et al Expression of matrix met alloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res. 22(3), 1813–1817 (2002).
   Google Scholar
• Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix met alloproteinase-9. I Clin. Oncol 14,3133–3140 (1996).
   Google Scholar
• Gohji K, Fujimoto N, Hara I et al. Serum matrix met alloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. I Cancer 79,96–101 (1998).
   Google Scholar
• Garbisa S, Scagliotti G, Masiero L et al. Correlation of serum matrix met alloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 15,4548–4549 (1992).
   Google Scholar
• Li L, Zhang S, Lin H, Lin JY. Relationship of expression unbalance of matrix met alloproteinase and tissue inhibitor of met alloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng 21(3), 305–310 (2002).
   Google Scholar
• Talvensaari-Mattila A, Paakko P, Blanco- Sequeiros G, Turpeenniemi-Hujanen T MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Peat. 58,287-293 (1999).
   Google Scholar
• Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Preoperative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. BE J. Cancer 83, 1425–1431 (2000).
   Google Scholar
• Poon RT, Ng TO, Lau C et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma. A prospective study. Ann. Surg. 233,227–235 (2001).
   Google Scholar
• Qian CN, Zhang CQ, Guo X et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer88, 2555–2561 (2000).
   Google Scholar
• Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. Uml. Clin. North Am. 27,191–197 (2000).
   PubMed Web of Science ®Google Scholar
• Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76, 2304–2311 (1995).
   PubMed Web of Science ®Google Scholar
• Wolff JM, Fandel T, Borchers H, Brehmer B Jr, Jakse G. Transforming growth factor-0 1 serum concentration in patients with prostatic cancer and benign prostatic hypertrophy. Brj Ural 81,403–405 (1998).
   Google Scholar
• Obermair A, Tempfer C, Hefler L et al. Concentration of vascular endothelial growth factor in the serum of patients with suspected ovarian cancer. BE J. Cancer 77, 1870–1874 (1998).
   Google Scholar
• Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5,823–829 (1999).
   Google Scholar
• Choe G, Park JK, Jouben-Steele L et al. Active matrix met alloproteinase-9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8(9), 2894–2901 (2002).
   Google Scholar
• Korem S, Kraiem Z, Shiloni E, Yehezkel 0, Sadeh 0, Resnick MB. Increased expression of matrix met alloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isc Med. Assoc. J. 4(4), 247–251 (2002).
   Google Scholar
• Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br. Cancer76, 1221–1227 (1997).
   Google Scholar
• Yamamoto Y, Toi M, Kondo S et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res. 2, 821–826 (1996).
   PubMed Web of Science ®Google Scholar
• Niedergethmann M, Hildenbrand R, Wostbrock B et al High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25(2), 122–129 (2002).
   PubMed Web of Science ®Google Scholar
• Koshiba T, Hosotani R, Wada M et al Involvement of matrix met alloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer82 (4) 642–650 (1998).
   Google Scholar
• Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Significance of matrix met alloproteinases and tissue inhibitors of met alloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Uml. 165, 1769–1772 (2001).
   Google Scholar
• Cai M, Onoda K, Takao M et al Degradation of tenascin-c and activity of matrix met alloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin. Cancer Res. 8(4), 1152–1156 (2002).
   Google Scholar
• Niu Q, Tang Z, Ma Z, Qin L, Bao W, Zhang L. Relationship between serum matrix met alloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcioma. Zhonghua Can Zang Bing Za Zhi 9 (Suppl.), 58–60 (2001).
   Google Scholar
• Yamamoto H, Itoh F, Adachi Y et al. Messenger RNA expression of matrix met alloproteinases and tissue inhibitors of met alloproteinases in human hepatocellular cancer. Jpn. I Clin. Oncol 29,58–62 (1999).
   PubMedGoogle Scholar
• Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor is associated with poor outcome in small-cell lung cancer. Int.j Cancer 17,144–146 (1998).
   Google Scholar
• Hyodo I, Doi T, Endo H et al Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.Eur. I Cancer34, 2041–2045 (1998).
   PubMed Web of Science ®Google Scholar
• Toi M, Bando H, Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer7 (4), 311–314 (2000).
   Google Scholar
• Inoue K, Kamada M, Slaton JW et al The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcioma of the renal pelvis and ureter. Clin. Cancer Res. 8(6), 1863–1870 (2002).
   Google Scholar
• Gupta VK, Jaskowiak NT, Beckett MA et al Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer 1 8(1), 47–54 (2002).
   Google Scholar
• Shintani S, Kiyota A, Mihara M et al Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn I Cancer Res. 91(10), 1051–1057 (2000).
   Google Scholar
• Geng L, Donnelly E, McMahon G et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61(6), 2413–2419 (2001).
   Google Scholar
• Lee CG, Heijn M, di Tomas° E et a/. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60(19), 5565–5570 (2000).
   PubMed Web of Science ®Google Scholar
• Dvorak HE Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Clin. Oncol 20(21), 4368–4380 (2002).
   Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2(10), 727–739 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 5 (Suppl. 1), 20–27 (2000).
   Google Scholar
• Harris AL. Von Hippel-Lindau syndrome: Target for antivascular endothelial growth factor receptor therapy. Oncologist 5 (Suppl. 1), 32–36 (2000).
   Google Scholar
• Giles FJ, Cooper MA, Silverman L et al Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor in patients with refractory myeloproliferative diseases. Cancer 97(8), 1920-1928 (2003).
   Google Scholar
• Camphausen K, Menard C. Angiogenesis inhibitors and radiotherapy of primary tumors. Exp. Opin. Biol. Ther 2 (5), 477–481 (2002).
   Google Scholar
• Dvorak H. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Clin. °rico'. 20(21), 4368–4380 (2002).
   Google Scholar
• Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist. 5\(Suppl. 1), 51–54 (2000).
   Google Scholar
• Teicher BA, Holden SA, Am G et al Anti- angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radial °rico'. Investig 2,269–276 (1995).
   Google Scholar
• •Breaking the traditional dogma.
   Google Scholar
• Jain RK. Normalizing tumor vasculature witih antiangiogenic therapy: a new paradigm for combination therapy. Nature Med. 7(9), 987–989 (2001).
   Google Scholar
• Gasparini G, Weidner N, Maluta S et al Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. int. Cancer55, 739–744 (1993).
   Google Scholar
• Koukourakis MI. Tumor angiogenesis and response to radiotherapy. Anticancer Res. 21(6B), 4285–4300 (2001).
   Google Scholar
• Takano S, Tsuboi K, Matsumura A, Nose T Antivascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neuro-oncol 5(1), 1–7 (2003).
   Google Scholar
• Mauceri HJ, Hanna NN, Beckett MA et al Combined effects of angiostatin and ionizing radiation in antitumor therapy. Natum 395(6690), 287–291 (1998).
   Google Scholar
• Hanna NN, Seetharam S, Mauceri HJ et al Antitumor interaction of short-course endostatin and ionizing radiation. Cancer" 6(5), 287–293 (2000).
   Google Scholar
• Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61(5), 2207–2211 (2001).
   Google Scholar
• Hess C, Vuong V, Hegyi I et al Effect of VEGF receptor inhibitor ptk787/zk222584 combined with ionizing radiation on endothelial cells and tumor growth. BE Cancer85(12), 2010-2016 (2001).
   Google Scholar
• Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation effects on tumor growth, vessel morphology and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res. 6,971-978 (2000).
   Google Scholar
• Ning S, Laird D, Cherrington JM, Knox SJ. The anti-angiogenic agents 5U5416 and 5U6668 increase the antitumor effects of fractionated irradiation. RadMt. Res. 157(1), 45–51 (2002).
   Google Scholar
• Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 62(6), 1702–1706 (2002).
   Google Scholar
• Cha S, Johnson G, Wadghiri YZ et al Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn. Reson. Med. 49(5), 848–855 (2003).
   Google Scholar
• Daldrup-Link HE, Brasch RC. Macromolecular contrast agents for MR mammography: current status. Eur Radial. 13(2), 354–365 (2003).
   Google Scholar
• Carriero A, Ambrossini R, Mattei PA, Angelucci D, Bonomo L. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. j Exp. Clin. Cancer Res. 21(3 Suppl.), 83–87 (2002).
   Google Scholar
• Marzola P, Farace P, Calderan L et al h7 ViVO mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. int. J. Cancer 104(4), 462–468 (2003).
   Google Scholar
• Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. j Magn. Reson. Imaging 16 (4), 407–422 (2002) .
   Google Scholar
• Gulec SA, Gaffga CM, Anthony CT, Su LJ, O'Leary JP, Woltering EA. Anti-angiogenic therapy with somatostatin receptor-mediated in situ radiation. Am. Surg. 67(11), 1068–1071 (2001).
   Google Scholar
• Shi W Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother 017C0i 66(1), 1–9 (2003).
   Google Scholar
• Perletti G, Concari P, Giardini R et al Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60,1793–1796 (2000).
   PubMed Web of Science ®Google Scholar
• Landuyt W Ahmed B, Nuyts S et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. j Radiat. Oncol Biol. Phys. 49(2), 443–450 (2001).
   Google Scholar
• Murata R, Nishimura Y, Hiraoka M. An anti-angiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. j Radial Oncol Biol. Phys. 37(5), 1107–1113 (1997).
   Google Scholar
• Greenberger JS. Antitumor interaction of short course endostatin and ionizing radiation. Cancer 1 6(5), 279–281 (2000).
   Google Scholar
• Minchinton Al, Fryer IKH, Wendt KR, Clow IKA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs7(3), 339–343 (1996).
   Google Scholar
• Gorski DH, Mauceri HJ, Salloum RM, Halpern A, Seetharam S, Weichselbaum RR. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res. 63,308–311 (2003).
   PubMedGoogle Scholar
• Gorski DH, Mauceri HJ, Salloum RM et al Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58(24), 5686–5689 (1998).
   Google Scholar
• Hari D, Beckett MA, Sukhatme VP et al Angiostatin induces mitotic cell death of proliferating endothelial cells. Ma Cell Biol. Res. Commun. 3(5), 277–282 (2000).
   Google Scholar